Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Minia 61519, Egypt.
Bioconjug Chem. 2022 Nov 16;33(11):1957-1972. doi: 10.1021/acs.bioconjchem.1c00479. Epub 2022 Jan 18.
Glioblastoma multiforme (GBM) is the most malignant type of brain tumor and has an extremely poor prognosis. Current treatment protocols lack favorable outcomes, and alternative treatments with superior efficacy are needed. In this study, we demonstrate that loading paclitaxel (PTX) in a polymeric, nanoparticulate delivery system is capable of improving its brain accumulation and therapeutic activity. We independently incorporated two different positively charged surface modifiers, poly(amidoamine) (PAMAM) and poly(ethylenimine) (PEI), onto poly(lactic--glycolic acid) (PLGA)-polyethylene glycol (PEG), PLGA-PEG, nanoparticles (NPs) using a modified nanoprecipitation technique that assures the formation of nanosized particles while exposing the positively charged polymer on the surface. The prepared NPs underwent comprehensive analyses of their size, charge, in vitro permeability against a BBB cell line, and in vivo biodistribution. Our results demonstrated the successful fabrication of positively charged NPs using PAMAM or PEI. Importantly, significant improvement in brain accumulation (in vivo) was associated with NPs containing PAMAM compared to unmodified NPs or NPs containing PEI. Finally, the efficacy of PAMAM-modified NPs loaded with PTX was evaluated with orthotopic human GBM xenografts in a mouse model, and the data demonstrated improved survival and equivalent safety compared to soluble PTX. Our data substantiate the importance of surface chemistry on the magnitude of NP accumulation in the brain and pave the way for further in vivo evaluation of chemotherapeutic drugs against GBM that have previously been overlooked because of their limited ability to cross the BBB.
多形性胶质母细胞瘤(GBM)是最恶性的脑肿瘤,预后极差。目前的治疗方案缺乏良好的效果,需要具有更好疗效的替代治疗方法。在这项研究中,我们证明了将紫杉醇(PTX)装载到聚合物纳米颗粒递药系统中能够提高其在脑内的蓄积和治疗活性。我们独立地将两种不同的带正电荷的表面修饰剂,聚(酰胺-胺)(PAMAM)和聚(亚乙基亚胺)(PEI),通过一种改良的纳米沉淀技术,装入聚(乳酸-乙醇酸)(PLGA)-聚乙二醇(PEG)、PLGA-PEG 纳米颗粒(NPs)中,该技术可确保形成纳米级颗粒,同时使带正电荷的聚合物暴露在表面上。对制备的 NPs 进行了尺寸、电荷、对 BBB 细胞系的体外渗透性以及体内分布的全面分析。结果表明,成功地使用 PAMAM 或 PEI 制备了带正电荷的 NPs。重要的是,与未修饰的 NPs 或含 PEI 的 NPs 相比,含 PAMAM 的 NPs 与脑内蓄积(体内)的显著改善相关。最后,用载有 PTX 的 PAMAM 修饰的 NPs 评估了其对原位人 GBM 异种移植物的疗效,数据表明与可溶性 PTX 相比,其具有更好的生存能力和等效的安全性。我们的数据证实了表面化学在 NP 在脑内蓄积程度上的重要性,并为进一步评估先前因穿过 BBB 的能力有限而被忽视的针对 GBM 的化疗药物的体内疗效铺平了道路。